# ATTICUS PHARMA INC: Phase 2: Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | ATTICUS PHARMA INC |
| Location | GREENVILLE, SC |
| Project | Phase 2: Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus |
| Project number | 1R44AR087266-01A1 |
| Mechanism | R44 |
| Institute | National Institute of Arthritis and Musculoskeletal and Skin Diseases |
| Award | $1,007,121 |
| Awarded | 2026-09-19 |
| Project period | 2026-09-25 to 2028-08-31 |
| UEI | LZXUMNXR3AB5 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11406639). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.